A 20-year-old female presented with a history of psoriasis and psoriatic arthritis since childhood. She started treatment with etanercept (Enbrel ®) 1 month previously. One day after a subcutaneous ...

THOUSAND OAKS, Calif., Nov. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement: Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel ® ...

May 23, 2005 — The European Commission has approved a 50-mg/mL formulation of etanercept injection for the treatment of rheumatoid arthritis, and the U.K.'s Medicine and Healthcare Products Regulatory ...

Whether starting or maintaining treatment, the Embark App has multiple features that can help patients on ENBREL throughout their treatment experience. As the healthcare industry continues to evolve ...

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...

KIRKLAND, QC, Sept. 15, 2020 /CNW/ - Merck Canada Inc., an affiliate of Merck & Co., Inc., known as MSD outside the United States and Canada, announced today that Health Canada has approved BRENZYS ®, ...

If you’re looking at treatment options for certain kinds of psoriasis or arthritis, you may want to learn more about Enbrel (etanercept). The active ingredient in Enbrel is etanercept. An active ...

The needle stays hidden during injection and a sensor can detect placement on skin. It also includes 3 difference injection speeds, a progress bar and a speaker. Amgen announced the availability of ...

SEATTLE, WA – Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has ...

BEIJING--(BUSINESS WIRE)--Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first ...

Amgen (NASDAQ:AMGN) today issued the following statement: Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel® (etanercept). This patent is owned by Hoffman-La Roche Inc.